Cryptococcal disease: implications of recent clinical trials on treatment and management. —
Research Profiles at Washington University School of Medicine Skip to main navigation Skip to …

Abstract Note from Dr. Merle A. Sande-The Cryptococcus has become a major cause of
meningitis in patients infected with the human immunodeficiency virus (HIV), and the …

Abstract Treatment of cryptococcal meningitis in patients with AIDS with amphotericin B plus
flucytosine is associated with a failure rate of 20%–30%. In the absence of chronic …

The optimum therapy for cryptococcal meningitis in patients with the acquired
immunodeficiency syndrome (AIDS) remains unresolved. Traditional therapy consists of …

A case of cryptococcal meningitis in a patient with the acquired immunodeficiency syndrome
(AIDS) is described, as well as the epidemiology, pathogenesis, clinical manifestations …

The optimum regimen for the treatment of cryptococcal meningitis in patients with AIDS is
still not totally clear. The triazoles fluconazole and itraconazole are associated with …

Abstract Dr. William G. Powderly provides a comprehensive review of the state of our
knowledge regarding cryptococcal infection in persons with infection due to human …

We studied the efficacy of oral itraconazole in 57 AIDS patients with cryptococcosis.
Diagnoses included cryptococcal meningitis (48 patients), cryptococcemia (28 patients) …

Thirty-one consecutive AIDS patients with cryptococcal disease were enrolled in a study of
the efficacy and safety of short-course primary treatment with a relatively high dose of …

Infection with HIV is the most common predisposing condition for developing cryptococcosis.
This chapter focuses on aspects that are specific to the coinfection of HIV and Cryptococcus …